Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a report issued on Thursday. They presently have a $9.00 target price on the biopharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 27.30% from the company’s previous close.

The analysts wrote, “Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia.””

Several other analysts have also recently commented on KERX. BidaskClub cut shares of Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research report on Wednesday, July 12th. Finally, ValuEngine cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.27.

Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 1.39% during midday trading on Thursday, hitting $7.07. The stock had a trading volume of 1,368,740 shares. The stock’s 50-day moving average is $6.96 and its 200-day moving average is $6.04. The company’s market cap is $766.85 million. Keryx Biopharmaceuticals has a one year low of $4.03 and a one year high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.03. The business had revenue of $11.82 million for the quarter, compared to the consensus estimate of $10.19 million. Keryx Biopharmaceuticals had a negative net margin of 387.12% and a negative return on equity of 1,122.28%. The business’s revenue was up 73.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.39) EPS. Equities analysts predict that Keryx Biopharmaceuticals will post ($0.69) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/20/maxim-group-reiterates-buy-rating-for-keryx-biopharmaceuticals-inc-nasdaqkerx.html.

Several institutional investors have recently made changes to their positions in KERX. Legal & General Group Plc raised its position in shares of Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the period. Shufro Rose & Co. LLC raised its position in shares of Keryx Biopharmaceuticals by 0.7% in the first quarter. Shufro Rose & Co. LLC now owns 73,200 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 500 shares during the period. Weiss Multi Strategy Advisers LLC raised its position in shares of Keryx Biopharmaceuticals by 1.6% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 1,000 shares during the period. Bank of America Corp DE raised its position in shares of Keryx Biopharmaceuticals by 1.0% in the first quarter. Bank of America Corp DE now owns 108,558 shares of the biopharmaceutical company’s stock valued at $669,000 after buying an additional 1,058 shares during the period. Finally, American International Group Inc. raised its position in shares of Keryx Biopharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 48,622 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 3,220 shares during the period. 62.27% of the stock is owned by institutional investors.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.